Morniflumate(CAS#65847-85-0)
Morniflumate(CAS#65847-85-0)
pharmachologic effect
Anti-inflammatory effect: It reduces arachidonic acid metabolism by inhibiting cyclooxygenase and 5-lipoxygenase pathways, which in turn reduces the synthesis of inflammatory mediators such as prostaglandins, leukotrienes, etc., and exerts anti-inflammatory effects.
Antipyretic effect: It can act on the body temperature regulation center, dilate the peripheral blood vessels, increase the blood flow to the skin, promote sweating, increase heat dissipation, and thus exert an antipyretic effect.
Analgesic effect: It can inhibit the synthesis of prostaglandins at the site of inflammation, reduce the stimulation of nerve endings by inflammatory reactions, and exert peripheral analgesic effects.
Clinical application
Inflammatory treatment in adults: It is used to treat inflammatory diseases affecting the respiratory tract, otolaryngology system, genitourinary tract and osteoarticular system.
Treatment of Pediatric Related Diseases: In Italy, maniflurate can also be used to treat pain associated with inflammation of the ear, nose and throat and gastrointestinal tract in children, especially upper respiratory tract infections.
Application
Morniflumate (CAS 65847-85-0), a non‑steroidal anti‑inflammatory drug (NSAID), is the β‑morpholinoethyl ester of niflumic acid. It serves as a prodrug that is rapidly hydrolyzed in plasma to release its active niflumic acid metabolite. This orally active NSAID acts by inhibiting both cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes, with a preferential effect on COX‑2, thereby reducing the synthesis of pro‑inflammatory prostaglandins. Morniflumate is indicated for symptomatic treatment of inflammatory conditions affecting the airways, ear‑nose‑throat (ENT) system, urogenital tract, and the osteoarticular system. It is particularly valued for a 30‑year clinical history of managing pain associated with pediatric ENT infections and soft‑tissue inflammation, offering a favorable gastrointestinal tolerability profile with reduced ulcerogenic risk compared to traditional NSAIDs. In pharmaceutical R&D, it is used as an API reference standard, anti‑inflammatory small‑molecule tool compound, and a subject of ongoing research into treating osteoarthritis, musculoskeletal disorders, and chronic bronchitis. As an optimized prodrug of niflumic acid, morniflumate represents an established advanced lead for developing next‑generation safer NSAID candidates. Xinchem offers high‑purity morniflumate with flexible custom synthesis, custom chemical synthesis, and reliable contract manufacturing, scaled from R&D to commercial volumes. Contact us today for a competitive quote and dependable global supply.
![6-[(4-Methylphenyl)Amino]-2-Naphthalenesulfonic acid （CAS# 7724-15-4)](https://www.xinchem.com/uploads/64MethylphenylAmino2Naphthalenesulfonicacid.png)
